Mirati

Normunity Announces $65 Million Series a Financing to Expand the Frontier of Precision Immuno-Oncology With Immune Normalizer Therapies

Retrieved on: 
Tuesday, October 25, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Diamond, AstraZeneca, Mirati, Bayer, Workflow, General partnership, Patient, Drug development, BMS, Director, Black Diamond, Partnership, Cancer, Yale school, Oncology, Immune system, Cancer research, Drug discovery, MD, Doctor of Philosophy, Nivolumab, Board, Pyxis, Ipilimumab, Yale School of Medicine, CMO, UTC, Sorafenib, PD-L1, Pharmaceutical industry, Vaccine, Dermatology, Medicine

Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million.

Key Points: 
  • Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million.
  • Normunitys new class of agents, called immune normalizers, target previously undiscovered mechanisms of immune disruption in cancer.
  • The normal immune system is a powerful anti-cancer force, and effective immune-stimulating strategies can result in long-lasting cancer remissions, even cures.
  • The Series A financing will enable Normunity to advance its emerging pipeline of immune normalizers into the clinic.

Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, October 25, 2022
SAN, LinkedIn, SOS1, U.S. Securities and Exchange Commission, Therapy, SEC, Life, Review, Science, PRMT5, NASDAQ, Patient, Twitter, Judgement, Cancer, Lung cancer, MTA, TAM, Pharmaceutical industry, Mirati, Facebook

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022.

Key Points: 
  • SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022.
  • ET / 1:30 p.m. PT on November 8, company executives will provide company updates and review financial results.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").
  • Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Verastem Oncology Appoints Anil Kapur to Board of Directors

Retrieved on: 
Thursday, October 20, 2022
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Actinium, CRAF, Regulation of tobacco by the U.S. Food and Drug Administration, RAMP, Birla Institute of Technology, Mesra, Program, NSCLC, Patent, ARAF, Board of directors, Shire, Mirati, Oncology, Baxalta, Amgen, MS, Commercial, MBA, Executive, Cancer, Fuqua School, Company, Marketing, FAK, Biomarker, Duke University, Verastem Oncology, Organization, Breakthrough therapy, Security (finance), Johnson & Johnson, Industrial engineering, Board, U.S. Securities and Exchange Commission, Government, Triple accreditation, SEC, MEK, Neoplasm, Patient, Business, BRAF, RAF, RAS, KRAS, Food, Geron Corporation, Strategic management, Louisiana Tech University, Bristol Myers Squibb, Management, Medical imaging, Pharmaceutical industry, Technology, Director

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.
  • Anils deep experience in oncology and his track record of product launch and commercial operations excellence will be invaluable as Verastem works to bring its lead compound RAF/MEK clamp VS-6766 in combinations across RAS-driven tumors to patients, said Michael Kauffman, M.D., Ph.D., Lead Director of the Verastem Oncology Board of Directors.
  • I am pleased to welcome Anil to the Board of Directors and believe he will be a tremendous source of strategic insights and guidance.
  • Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, October 5, 2022
SAN, LinkedIn, SOS1, Cyprus Securities and Exchange Commission, RSU, Therapy, SEC, Life, Science, PRMT5, Employment, NASDAQ, Patient, Twitter, Judgement, Cancer, Lung cancer, MTA, U.S. Securities and Exchange Commission, TAM, Pharmaceutical industry, Mirati, Facebook

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $68.36 per share, which is equal to the closing price of Mirati's common stock on October 3, 2022, (the "Grant Date").
  • Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

Retrieved on: 
Tuesday, October 4, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Part, RAMP, Cancer, ARAF, MEK, Verastem Oncology, Neoplasm, CRAF, SEC, KRAS, Review, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Government, Food, Cohort, Patent, Mirati, FDA, BRAF, RAF, Pancreatic Cancer Action Network, Oncology, Pancreatic cancer, ORR, Partnership, U.S. Securities and Exchange Commission, Safety, RAS, Program, Security (finance), Patient, Interim, FAK, Investment, Breakthrough therapy, Intellectual property, Amgen, Company, Pharmaceutical industry, Medical imaging, NSCLC

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP (Raf And Mek Program) clinical trials.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP (Raf And Mek Program) clinical trials.
  • Verastem recently conducted a second planned interim analysis of the ongoing RAMP 201 trial among patients with recurrent LGSOC.
  • Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp in RAS-driven tumors as part of its (Raf And Mek Program).
  • Verastem Oncology has established clinical collaborations with Amgen and Mirati to evaluate LUMAKRAS (sotorasib) and adagrasib in combination with VS-6766 in KRAS G12C mutant NSCLC as part of the RAMP 203 and RAMP 204 trials, respectively.

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

Retrieved on: 
Thursday, September 22, 2022
Therapy, Twitter, PRMT5, U.S. Securities and Exchange Commission, LinkedIn, Life, Judgement, Lung cancer, Patient, Bank, Cancer, MTA, Science, NASDAQ, SAN, Conference, SEC, Webcast, SOS1, TAM, Pharmaceutical industry, Mirati, Facebook

SAN DIEGO, Sept. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.

Key Points: 
  • SAN DIEGO, Sept. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
  • Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").
  • Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati.

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

Retrieved on: 
Wednesday, August 31, 2022
Lung cancer, PRMT5, SOS1, Cancer, Therapy, SAN, NASDAQ, Judgement, LinkedIn, Science, SEC, U.S. Securities and Exchange Commission, MTA, Conference, TAM, Twitter, Webcast, Bank, Life, BST, Patient, Pharmaceutical industry, News, Mirati, Facebook

SAN DIEGO, Aug. 31, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.

Key Points: 
  • SAN DIEGO, Aug. 31, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
  • Laurie Stelzer , chief financial officer, and Ben Hickey , chief commercial officer, will represent the company in a fireside chat.
  • Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, August 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research and development, U.S. Securities and Exchange Commission, Everolimus, Survival, ASCO, CEO, SEC, Patent, Cancer, Clinical trial, Investment, Security (finance), RAMP, Patient, BRAF, KRAS, Journal of Transportation Engineering, Part B: Pavements, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, General Administration of Sport of China, Part, Sale, Breakthrough therapy, Government, FAK, Pancreatic cancer, ARAF, Table, RAF, Verastem Oncology, RAS, American Society of Clinical Oncology, Income, NSCLC, Oncology, Mission statement, Amgen, Mirati, Â, CRAF, Achievement, Society, Review, Company, GAAP, Research, MEK, Progression-free survival, Pharmaceutical industry, Bank, Medical imaging

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.
  • The Company plans to complete enrollment of all four cohorts of the trial in the second half of this year.
  • The Company expects to report topline results from Part A, initiate Part B and discuss the data with regulatory authorities during the second half of 2022.
  • Verastem Oncology ended the second quarter 2022 with cash, cash equivalents and investments of $94.3 million.

Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Wednesday, July 20, 2022
U.S. Securities and Exchange Commission, Twitter, SAN, SEC, SOS1, Judgement, TAM, Therapy, NASDAQ, Cancer, MTA, Review, Lung cancer, Science, PRMT5, Patient, LinkedIn, Life, Pharmaceutical industry, Mirati, Facebook

SAN DIEGO, July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022.

Key Points: 
  • SAN DIEGO, July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022.
  • ET / 1:30 p.m. PT on August 3, company executives will provide company updates and review financial results.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").
  • Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Adamis Appoints Vickie Reed to Board of Directors

Retrieved on: 
Thursday, May 26, 2022
Senior, Anaphylaxis, Market for corporate control, Naloxone, Mirati, Private Securities Litigation Reform Act, Annual report, Nasdaq, 4-Hydroxy-TEMPO, Telecommunication, Patient, Goal, Form 10-K, Therapy, Amylin Pharmaceuticals, Emergency, ADMP, COVID-19, Bristol Myers Squibb, Guy Adami, FDA, SAN, Accounting, Allergy, Biotechnology, Adrenaline, Board, University, LinkedIn, PricewaterhouseCoopers, University of Colorado Denver Business School, Twitter, Director, SEC, Opioid overdose, Controller, Certified Public Accountant, GLOBE, Management, Pharmaceutical industry, Finance

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the companys board of directors.

Key Points: 
  • SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the companys board of directors.
  • Richard Williams, Chairman of the Board, commented: We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value.
  • I am looking forward to working with other members of the Adamis Board of Directors and the management team to advance the companys goals and further its corporate, regulatory and commercial strategies, said Ms. Reed.
  • She is also a member of the board of directors of Evoke Pharma.